Mobile

A single-dose, open-label, randomized, 2-way crossover, clinical pharmacology study of four inhalations of CHF 1535 100/6 NEXT DPI® (fixed combination of beclomethasone dipropionate 100μg plus formote...

Mise à jour : Il y a 4 ans
Référence : EUCTR2010-024384-40

A single-dose, open-label, randomized, 2-way crossover, clinical pharmacology study of four inhalations of CHF 1535 100/6 NEXT DPI® (fixed combination of beclomethasone dipropionate 100μg plus formoterol fumarate 6 μg) versus the same dose of CHF 1535 100/6 pMDI both administered with charcoal block

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To compare the lung bioavailability of B17MP (active metabolite of BDP) and formoterol after four inhalations using CHF 1535 100/6 NEXT DPI® and CHF 1535 100/6 pMDI using AeroChamber PlusTM spacer, with activated charcoal to block gastrointestinal absorption.

Critère d'inclusion

  • Asthma

Liens